BCR and chronic myelogenous leukemia, BCR-ABL1 positive: To investigate the cellular mechanisms underlying the increased molecular response of the statin/TKI in patients with CML undergoing imatinib therapy, the effects of statins (rosuvastatin and atorvastatin), TKIs (IM, NI, or DA), or various combinations and concentrations of TKIs and statins on the viability of K562 BCR-ABL1+ cells were examined.